| Parameter | Inclusion criteria | Exclusion criteria |
| Population | Female and male patients over the age of 30 with a clinical diagnosis of PD consistent with the UK Brain Bank criteria who have a Hoehn and Yahr Stage 3 or less during ON state or less than 5 during OFF state, who take optimized Levodopa doses more than once a day, and whose optimized Levodopa doses have been maintained stable for at least two weeks | Patients with previous neurosurgical intervention for PD, patients with a mini-mental state examination score of 26 or less, patients with a clinically significant and unstable medical, surgical, or psychiatric illness, or patients with a history of melanoma or significant skin disorders |
| Intervention | Subcutaneous liquid Levodopa-Carbidopa ND0612 | Other types of Levodopa-Carbidopa medication |
| Comparator | No comparator | No comparator |
| Outcome | UPDRS Part II and Part III as efficacy endpoints | UPDRS Part II and Part III not included as efficacy endpoints |
| Study design | Randomized Controlled Trials published in English | Expert opinions, editorials, case reports, abstracts without full reports, and preprints. Published in any other language than English |